{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Total Neoadjuvant Therapy with Chemoimmunotherapy in High-Risk pMMR Rectal Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This single-arm phase 2 trial was conducted at the Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, from June 2020 to October 2021."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were patients with high-risk pMMR rectal cancer."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention included 3 cycles of induction oxaliplatin and capecitabine combined with camrelizumab, followed by radiotherapy (50.6 Gy in 22 fractions) with concurrent capecitabine."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the pathologic complete response rate, measured at the end of treatment."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and blinding details were not applicable as this was a single-arm study."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Randomisation and blinding details were not applicable as this was a single-arm study."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 25 patients enrolled (19 men, 6 women; median age 58 years), 22 completed the TNT schedule."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The pathologic complete response rate was 33.3% (7/21)."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The pathologic complete response rate was 33.3% (7/21)."
      },
      "Harms": {
        "score": 1,
        "evidence": "The most common adverse event was nausea (80%); grade 3 toxic effects occurred in 36% of patients."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      }
    },
    "total_score": 13,
    "max_score": 25
  },
  "model": "gpt-4o"
}